Min-Jiang Chen (Minjiang Chen)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 24

Top Topics

Circulating Tumor

Systemic Lupus Erythematosus

Tyrosine Kinase

Top Venues

Thoracic cancer

Cancer management and research

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Min-Jiang Chen, Pengfei Ma, Yong-Chang Zhang, Dong Wang, Zhuang Yu, Yujie Fu, Xiaojing Zhao, Mengzhao Wang, Guanglei Zhuang, Ying Jing
Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma. Journal for immunotherapy of cancer 11 (10) (2023)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer 14 (8) (2023)
Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Qing Zhou, Xiangning Liu, Ji Li, Bing Tong, Yan Xu, Min-Jiang Chen, Xiaoyan Liu, Xiaoxing Gao, Yuequan Shi, Jing Zhao, Wei Zhong, Mengzhao Wang
Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Qing Zhou, Xiangning Liu, Ji Li, Bing Tong, Yan Xu, Min-Jiang Chen, Xiaoyan Liu, Xiaoxing Gao, Yuequan Shi, Jing Zhao, Wei Zhong, Mengzhao Wang
Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer. Thoracic cancer (2023)
Haoran Zhang, Dongming Zhang, Jia Liu, Yuequan Shi, Xiaoyan Liu, Min-Jiang Chen, Wei Zhong, Jing Zhao, Yan Xu, Mengzhao Wang
Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC. Thoracic cancer (2023)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer 14 (8) (2023)
Qing Zhou, Xiangning Liu, Ji Li, Bing Tong, Yan Xu, Min-Jiang Chen, Xiaoyan Liu, Xiaoxing Gao, Yuequan Shi, Jing Zhao, Wei Zhong, Mengzhao Wang
Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer (2023)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer 14 (8) (2023)
Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer (2023)
Xiao-Yan Si, Xueqing Zheng, Xinlun Tian, Hanping Wang, Yan Xu, Jing Zhao, Min-Jiang Chen, Wei Zhong, Mengzhao Wang, Li Zhang, Xiao-Tong Zhang
Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case-control study. Thoracic cancer (2023)
Xiaoxing Gao, Ruili Pan, Min-Jiang Chen, Jing Zhao, Wei Zhong, Hanping Wang, Xiao-Yan Si, Xiao-Tong Zhang, Li Zhang, Yan Xu, Mengzhao Wang
Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. Thoracic cancer 13 (7) (2022)
Bei Tan, Yun-Xin Liu, Hao Tang, Dan Chen, Yan Xu, Min-Jiang Chen, Yue Li, Meng-Zhao Wang, Jia-Ming Qian
Gut microbiota shed new light on the management of immune-related adverse events. Thoracic cancer 13 (19) (2022)
Bei Tan, Min-Jiang Chen, Qi Guo, Hao Tang, Yue Li, Xin-Miao Jia, Yan Xu, Liang Zhu, Meng-Zhao Wang, Jia-Ming Qian
Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events. Thoracic cancer 12 (12) (2021)
Jun Ni, Xiao-Tong Zhang, Hanping Wang, Xiao-Yan Si, Yan Xu, Jing Zhao, Min-Jiang Chen, Li Zhang, Mengzhao Wang
Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period. Thoracic cancer 13 (4) (2021)
Yuequan Shi, Xiaoyan Liu, Juan Du, Dongming Zhang, Jia Liu, Min-Jiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang
Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. Thoracic cancer (2021)
Min-Jiang Chen, Yan Xu, Jing Zhao, Ji Li, Xiangning Liu, Wei Zhong, Mengzhao Wang
Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer. Thoracic cancer 12 (17) (2021)
Yuequan Shi, Ji Li, Min-Jiang Chen, Hongsheng Liu, Dongjie Ma, Yuxiao Lin, Mengzhao Wang, Yan Xu
Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response. Thoracic cancer (2021)
Xiaoling Qiu, Hongge Liang, Wei Zhong, Jing Zhao, Min-Jiang Chen, Zhaohui Zhu, Yan Xu, Mengzhao Wang
Prognostic impact of maximum standardized uptake value on 18 F-FDG PET/CT imaging of the primary lung lesion on survival in advanced non-small cell lung cancer: A retrospective study. Thoracic cancer 12 (6) (2021)
Yuequan Shi, Jian Fang, Cheng-Zhi Zhou, Anwen Liu, Yan Wang, Qingwei Meng, Cuimin Ding, Bin Ai, Yangchun Gu, Yu Yao, Hong Sun, Hui Guo, Cuiying Zhang, Xia Song, Junling Li, Bei Xu, Zhiqiang Han, Meijun Song, Tingyu Tang, Peifeng Chen, Hongmin Lu, Yongjie Shui, Guangyuan Lou, Dongming Zhang, Jia Liu, Xiaoyan Liu, Xiangning Liu, Xiaoxing Gao, Qing Zhou, Min-Jiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. Thoracic cancer 13 (3) (2021)
Min-Jiang Chen, Qiang Li, Yan Xu, Jing Zhao, Li Zhang, Lijuan Wei, Wei Zhong, Mengzhao Wang
Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. Thoracic cancer 11 (7) (2020)
Hongge Liang, Di Ma, Yan Xu, Jing Zhao, Min-Jiang Chen, Xiaoyan Liu, Wei Zhong, Junling Li, Mengzhao Wang
Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib. Cancer management and research 11 (2019)